1/11

Figure 1


N A13
N A13
N G12

A9
N G8
N G8
N G8
A6
Comain II N A6
Comain I

b

С

Figure 2



helix III

5' Y<sup>32</sup><sub>P</sub>CUCGGUACCGUUGAUCCUGUCUUGCAUAA - biotin 3'

3' OHGAGCCAUGGCAACUAGGA

AACGUAACCCGG<sub>PPP</sub> 5'

N18

N18g0

helix III IL2 helix I

5' Y<sup>32</sup>PCUCGGUACCGUUGAUCCUGUCUUGCAUAA - biotin 3'

3' OHGAGCCAUGGCAACUAGGACA AACGUAACCCGGGPPP 5'

Kpn1 C U


A UA

A G

12G A9

11.1 C G10.1 N4g0

Figure 3



#### 4/11

#### Figure 4






Figure 5



b



## Figure 6

#### **NNHH** YRHH pyrimidine rich class CGUU subclass (II) I UGUU тино UAAC 3 שטטט UUAC 4 WYHH υυcc טטטכ 2 ACCC 3 UUUA 2 class UUUA II UCCC AUUC AUUA **GHHA** class III GUAA 2 GAUA

Figure 7




Figure 8






Figure 9



#### Figure 10

# In-vitro cleavage of PDGF transcript (637bp) by PDGF293 MR7-11 miniribozymes







Figure 11

## Ribonuclease protection assay of PDGF mRNA



#### 11/11

Figure 12

## Optimization of PDGF293 MR9 miniribozyme activity in PDGF expressing CHO cells

